Honokiol Clinical Trials

Size	Price	Qty
10mg	USD 147
1g	USD 1,870

Clinical Trials

Multiple clinical trials are currently evaluating the therapeutic potential of honokiol in Phase 1 and Phase 3 studies targeting non-small-cell lung carcinoma and acne vulgaris. These investigations are sponsored by individual clinical investigators alongside academic and medical research institutes, such as The Methodist Hospital Research Institute. With recruitment statuses ranging from actively recruiting to not yet recruiting, these studies demonstrate ongoing clinical evaluation of honokiol across diverse indications.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06566443	RECRUITING	Carcinoma, Non-Small-Cell Lung	The Methodist Hospital Research Institute	2025-02-13	PHASE1
NCT06775314	NOT_YET_RECRUITING	Acne Vulgaris	Dr.dr.Irma Bernadette, SpKK (K)	2025-03-01	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-05-28)

Check the Honokiol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Honokiol inhibits Akt phosphorylation and modulates the ROS/ERK1/2 and nuclear factor kappa B signaling pathways, thereby downregulating critical pro-survival and angiogenic factors such as COX-2 and VEGF. This targeted pathway inhibition induces G0/G1 cell cycle arrest, caspase-dependent apoptosis, and autophagy, providing a mechanistic rationale for suppressing cell proliferation and tumor progression in conditions such as non-small-cell lung carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).